Pharma Blog Watch

Merck's CETP Inhibitor (Pharma's Market)
In his blog, Mike Huckman discusses Merck's revelation this week that "it has a so-called CETP inhibitor in the drug development pipeline."

"That's the same type of drug that Pfizer pulled the plug on last week because of an increased risk of death," he writes. "But in a two-month-long clinical trial Merck says it saw no serious heart problems. Keep in mind that Pfizer's independent safety data monitoring board did not see a problem with torcetrapib until patients used it for 18 to 20 months."